Analyst ratings often influence investor sentiment. The reiteration of an Outperform rating by a reputable analyst like Robert Driscoll could boost investor confidence in Zentalis Pharma. The maintained price target of $38 also indicates that the analyst sees potential for the stock's price to rise, which could further encourage investment.